Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached.
Wilcock DJ, Badrock AP, Wong CW, Owen R, Guerin M, Southam AD, Johnston H, Telfer BA, Fullwood P, Watson J, Ferguson H, Ferguson J, Lloyd GR, Jankevics A, Dunn WB, Wellbrock C, Lorigan P, Ceol C, Francavilla C, Smith MP, Hurlstone AFL. Wilcock DJ, et al. Among authors: lorigan p. Cell Rep. 2022 Jun 21;39(12):110995. doi: 10.1016/j.celrep.2022.110995. Cell Rep. 2022. PMID: 35732120 Free PMC article.
Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish.
Henderson F, Johnston HR, Badrock AP, Jones EA, Forster D, Nagaraju RT, Evangelou C, Kamarashev J, Green M, Fairclough M, Ramirez IB, He S, Snaar-Jagalska BE, Hollywood K, Dunn WB, Spaink HP, Smith MP, Lorigan P, Claude E, Williams KJ, McMahon AW, Hurlstone A. Henderson F, et al. Among authors: lorigan p. Cancer Res. 2019 May 1;79(9):2136-2151. doi: 10.1158/0008-5472.CAN-18-2409. Epub 2019 Mar 12. Cancer Res. 2019. PMID: 30862716
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.
Wong CW, Evangelou C, Sefton KN, Leshem R, Zhang W, Gopalan V, Chattrakarn S, Fernandez Carro ML, Uzuner E, Mole H, Wilcock DJ, Smith MP, Sergiou K, Telfer BA, Isaac DT, Liu C, Perl NR, Marie K, Lorigan P, Williams KJ, Rao PE, Nagaraju RT, Niepel M, Hurlstone AFL. Wong CW, et al. Among authors: lorigan p. Nat Commun. 2023 Sep 26;14(1):5983. doi: 10.1038/s41467-023-41737-1. Nat Commun. 2023. PMID: 37752135 Free PMC article.
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Girotti MR, et al. Among authors: lorigan p. Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. Cancer Cell. 2015. PMID: 25500121 Free PMC article.
Circulating Tumour DNA in Melanoma-Clinic Ready?
Tivey A, Britton F, Scott JA, Rothwell D, Lorigan P, Lee R. Tivey A, et al. Among authors: lorigan p. Curr Oncol Rep. 2022 Mar;24(3):363-373. doi: 10.1007/s11912-021-01151-6. Epub 2022 Feb 8. Curr Oncol Rep. 2022. PMID: 35133615 Free PMC article. Review.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: lorigan p. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ. Spender LC, et al. Among authors: lorigan p. Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226. Oncotarget. 2016. PMID: 27835901 Free PMC article.
The role of nivolumab in melanoma.
Gomes F, Serra-Bellver P, Lorigan P. Gomes F, et al. Among authors: lorigan p. Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12. Future Oncol. 2018. PMID: 29328782 Review.
296 results